Ernest Nadal
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”(IT)Bellvitge University Hospital(ES)Institut d'Investigació Biomédica de Bellvitge(ES)Institut Català d'Oncologia(ES)Duran i Reynals Hospital(ES)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, RNA modifications and cancer
Most-Cited Works
- → Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial(2020)798 cited
- → Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial(2019)601 cited
- → Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer(2023)410 cited
- → Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)(2022)327 cited
- → SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo(2018)313 cited
- → KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target(2018)